However, additional genes highly relevant to BCP-ALL were not included in the four panels design, such as TP53, CSF1R, or NF1. Therefore, when choosing an NGS panel for BCP-ALL, it might be important to prioritize the panel that includes the relevant genes with diagnostic, prognostic, and/or predictive value according to the current therapeutic protocols. The gene discussed is CSF1R; the disease is acute lymphoblastic leukemia.